181 related articles for article (PubMed ID: 27128693)
1. Assessing the Prognostic Significance of Histologic Response in Osteosarcoma: A Comparison of Outcomes on CCG-782 and INT0133-A Report From the Children's Oncology Group Bone Tumor Committee.
Bishop MW; Chang YC; Krailo MD; Meyers PA; Provisor AJ; Schwartz CL; Marina NM; Teot LA; Gebhardt MC; Gorlick R; Janeway KA; Chou AJ
Pediatr Blood Cancer; 2016 Oct; 63(10):1737-43. PubMed ID: 27128693
[TBL] [Abstract][Full Text] [Related]
2. Multiple drug resistance in osteogenic sarcoma: INT0133 from the Children's Oncology Group.
Schwartz CL; Gorlick R; Teot L; Krailo M; Chen Z; Goorin A; Grier HE; Bernstein ML; Meyers P;
J Clin Oncol; 2007 May; 25(15):2057-62. PubMed ID: 17513810
[TBL] [Abstract][Full Text] [Related]
3. Treatment of nonmetastatic osteosarcoma of the extremity with preoperative and postoperative chemotherapy: a report from the Children's Cancer Group.
Provisor AJ; Ettinger LJ; Nachman JB; Krailo MD; Makley JT; Yunis EJ; Huvos AG; Betcher DL; Baum ES; Kisker CT; Miser JS
J Clin Oncol; 1997 Jan; 15(1):76-84. PubMed ID: 8996127
[TBL] [Abstract][Full Text] [Related]
4. Outcome for adolescent and young adult patients with osteosarcoma: a report from the Children's Oncology Group.
Janeway KA; Barkauskas DA; Krailo MD; Meyers PA; Schwartz CL; Ebb DH; Seibel NL; Grier HE; Gorlick R; Marina N
Cancer; 2012 Sep; 118(18):4597-605. PubMed ID: 22252521
[TBL] [Abstract][Full Text] [Related]
5. Prognostic nomogram for predicting the 5-year probability of developing metastasis after neo-adjuvant chemotherapy and definitive surgery for AJCC stage II extremity osteosarcoma.
Kim MS; Lee SY; Lee TR; Cho WH; Song WS; Koh JS; Lee JA; Yoo JY; Jeon DG
Ann Oncol; 2009 May; 20(5):955-60. PubMed ID: 19153123
[TBL] [Abstract][Full Text] [Related]
6. Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols.
Kager L; Zoubek A; Pötschger U; Kastner U; Flege S; Kempf-Bielack B; Branscheid D; Kotz R; Salzer-Kuntschik M; Winkelmann W; Jundt G; Kabisch H; Reichardt P; Jürgens H; Gadner H; Bielack SS;
J Clin Oncol; 2003 May; 21(10):2011-8. PubMed ID: 12743156
[TBL] [Abstract][Full Text] [Related]
7. Can pretreatment
Song H; Jiao Y; Wei W; Ren X; Shen C; Qiu Z; Yang Q; Wang Q; Luo QY
Eur Radiol; 2019 Jul; 29(7):3945-3954. PubMed ID: 30859285
[TBL] [Abstract][Full Text] [Related]
8. Multiinstitutional phase II study of neoadjuvant chemotherapy for osteosarcoma (NECO study) in Japan: NECO-93J and NECO-95J.
Iwamoto Y; Tanaka K; Isu K; Kawai A; Tatezaki S; Ishii T; Kushida K; Beppu Y; Usui M; Tateishi A; Furuse K; Minamizaki T; Kawaguchi N; Yamawaki S
J Orthop Sci; 2009 Jul; 14(4):397-404. PubMed ID: 19662473
[TBL] [Abstract][Full Text] [Related]
9. Proximal tumor location and fluid-fluid levels on MRI predict resistance to chemotherapy in stage IIB osteosarcoma.
Jeon DG; Song WS; Cho WH; Kong CB; Cho SH
Clin Orthop Relat Res; 2014 Jun; 472(6):1911-20. PubMed ID: 24574120
[TBL] [Abstract][Full Text] [Related]
10. Impact of chemotherapy-induced necrosis on event-free and overall survival after preoperative MAP chemotherapy in patients with primary high-grade localized osteosarcoma.
Tsuda Y; Tsoi K; Parry MC; Stevenson JD; Fujiwara T; Sumathi V; Jeys LM
Bone Joint J; 2020 Jun; 102-B(6):795-803. PubMed ID: 32475245
[TBL] [Abstract][Full Text] [Related]
11. High-BMI at diagnosis is associated with inferior survival in patients with osteosarcoma: a report from the Children's Oncology Group.
Altaf S; Enders F; Jeavons E; Krailo M; Barkauskas DA; Meyers P; Arndt C
Pediatr Blood Cancer; 2013 Dec; 60(12):2042-6. PubMed ID: 23955975
[TBL] [Abstract][Full Text] [Related]
12. Non-Hodgkin's lymphoma arising in bone in children and adolescents is associated with an excellent outcome: a Children's Cancer Group report.
Lones MA; Perkins SL; Sposto R; Tedeschi N; Kadin ME; Kjeldsberg CR; Wilson JF; Zwick DL; Cairo MS
J Clin Oncol; 2002 May; 20(9):2293-301. PubMed ID: 11981000
[TBL] [Abstract][Full Text] [Related]
13. Effect of time to resumption of chemotherapy after definitive surgery on prognosis for non-metastatic osteosarcoma.
Imran H; Enders F; Krailo M; Sim F; Okuno S; Hawkins D; Neglia J; Randall RL; Womer R; Mascarenhas L; Arndt CA
J Bone Joint Surg Am; 2009 Mar; 91(3):604-12. PubMed ID: 19255220
[TBL] [Abstract][Full Text] [Related]
14. Outcome of Patients With Recurrent Osteosarcoma Enrolled in Seven Phase II Trials Through Children's Cancer Group, Pediatric Oncology Group, and Children's Oncology Group: Learning From the Past to Move Forward.
Lagmay JP; Krailo MD; Dang H; Kim A; Hawkins DS; Beaty O; Widemann BC; Zwerdling T; Bomgaars L; Langevin AM; Grier HE; Weigel B; Blaney SM; Gorlick R; Janeway KA
J Clin Oncol; 2016 Sep; 34(25):3031-8. PubMed ID: 27400942
[TBL] [Abstract][Full Text] [Related]
15. Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy: 15-year experience in 789 patients treated at a single institution.
Bacci G; Longhi A; Versari M; Mercuri M; Briccoli A; Picci P
Cancer; 2006 Mar; 106(5):1154-61. PubMed ID: 16421923
[TBL] [Abstract][Full Text] [Related]
16. Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival--a report from the Children's Oncology Group.
Meyers PA; Schwartz CL; Krailo MD; Healey JH; Bernstein ML; Betcher D; Ferguson WS; Gebhardt MC; Goorin AM; Harris M; Kleinerman E; Link MP; Nadel H; Nieder M; Siegal GP; Weiner MA; Wells RJ; Womer RB; Grier HE;
J Clin Oncol; 2008 Feb; 26(4):633-8. PubMed ID: 18235123
[TBL] [Abstract][Full Text] [Related]
17. Neoadjuvant chemotherapy for osteosarcoma of the extremity: intensification of preoperative treatment does not increase the rate of good histologic response to the primary tumor or improve the final outcome.
Bacci G; Forni C; Ferrari S; Longhi A; Bertoni F; Mercuri M; Donati D; Capanna R; Bernini G; Briccoli A; Setola E; Versari M
J Pediatr Hematol Oncol; 2003 Nov; 25(11):845-53. PubMed ID: 14608193
[TBL] [Abstract][Full Text] [Related]
18. Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy: a randomized phase III trial of the European Osteosarcoma Intergroup.
Lewis IJ; Nooij MA; Whelan J; Sydes MR; Grimer R; Hogendoorn PC; Memon MA; Weeden S; Uscinska BM; van Glabbeke M; Kirkpatrick A; Hauben EI; Craft AW; Taminiau AH; ;
J Natl Cancer Inst; 2007 Jan; 99(2):112-28. PubMed ID: 17227995
[TBL] [Abstract][Full Text] [Related]
19. Outcomes in non-metastatic treatment naive extremity osteosarcoma patients treated with a novel non-high dosemethotrexate-based, dose-dense combination chemotherapy regimen 'OGS-12'.
Bajpai J; Chandrasekharan A; Talreja V; Simha V; Chandrakanth MV; Rekhi B; Khurana S; Khan A; Vora T; Ghosh J; Banavali SD; Gupta S
Eur J Cancer; 2017 Nov; 85():49-58. PubMed ID: 28888849
[TBL] [Abstract][Full Text] [Related]
20. Phase 2 study for nonmetastatic extremity high-grade osteosarcoma in pediatric and adolescent and young adult patients with a risk-adapted strategy based on ABCB1/P-glycoprotein expression: An Italian Sarcoma Group trial (ISG/OS-2).
Palmerini E; Meazza C; Tamburini A; Bisogno G; Ferraresi V; Asaftei SD; Milano GM; Coccoli L; Manzitti C; Luksch R; Serra M; Gambarotti M; Donati DM; Scotlandi K; Bertulli R; Favre C; Longhi A; Abate ME; Perrotta S; Mascarin M; D'Angelo P; Cesari M; Staals EL; Marchesi E; Carretta E; Ibrahim T; Casali PG; Picci P; Fagioli F; Ferrari S
Cancer; 2022 May; 128(10):1958-1966. PubMed ID: 35201621
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
